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Plaque assays for titrating dengue virus (DENV) are time-consuming and not suitable for strains that do not
plaque. Fluorescence-activated cell sorting (FACS) has been used to detect DENV-infected cells. Here we
describe a FACS-based assay for titrating DENV. We determined that at 24 h postinfection, the number of
infected cells detected by FACS represented the first round of infection and therefore could be used as a
readout of the number of infectious particles in the inoculum. When the titers of different laboratory and
clinical strains of DENV were compared using FACS, plaque, and endpoint dilution assays, for most strains
the FACS titers were comparable to titers obtained by plaque or endpoint dilution assays. The FACS assay is
an improvement over the plaque assay because the infection period is reduced from 5 to 7 days to 24 h and the
assay can be used to titrate clinical isolates that frequently do not form clear plaques on cell monolayers. The
novel FACS-based methods described here will facilitate laboratory studies of dengue.
Dengue is a mosquito-borne viral disease of global public
health significance. Throughout the world there are more than
2.5 billion people at risk of dengue virus (DENV) infection.
Each year there are an estimated 100 million cases of dengue
viral infection worldwide, with 250,000 people developing the
more severe dengue hemorrhagic fever/dengue shock syn-
drome, which is often fatal (5). DENV is a positive-polarity
RNA virus in the family Flaviviridae, and the DENV complex
consists of four distinct serotypes designated DENV1 through
DENV4 (10).
Laboratory studies of dengue virus are difficult because the
virus does not grow to high titers in cell culture and assays for
titrating virus and measuring virus neutralization are time-
consuming. These problems are exacerbated when working
with primary clinical isolates of virus. Standard methods for
titrating DENV and measuring the ability of antisera to neu-
tralize the virus are based on plaque assays which require 5 to
7 days to complete. Some isolates, especially among primary
clinical isolates, do not form clear plaques on cell monolayers.
Better methods for titrating the virus and measuring the ability
of antisera to neutralize dengue need to be developed. Within
the past 10 years, fluorescence-activated cell sorter (FACS)-
based methods have been developed to follow infection and
determine titers of viruses such as human immunodeficiency
virus, herpesvirus, measles virus, influenza virus, Epstein-Barr
virus, and rabies virus (1, 4, 12, 13, 16). FACS has also been
used to detect DENV in clinical samples and to measure the
ability of the virus to infect a variety of cells (2, 3, 7, 8, 11, 17).
Here we report on a FACS-based assay for titrating DENVs
and for characterizing the ability of antisera to neutralize the
virus.
MATERIALS AND METHODS
Cells, viruses, and antisera. Aedes albopictus C6/36 mosquito cells were ob-
tained from the Centers for Disease Control and Prevention, Fort Collins. Vero
76 (African Green monkey kidney) cells were purchased from the American
Type Culture Collection (Manassas, VA). C6/36 cells were maintained in Eagle’s
minimum essential medium (EMEM; Gibco BRL) supplemented with 10%
heat-inactivated fetal bovine serum (FBS), penicillin G (100 U/ml), streptomycin
(100 g/ml), L-glutamine, and nonessential amino acids at 28°C in 5% CO2. Vero
76 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM)–F-12
(Gibco BRL) containing 115 mM HEPES buffer supplemented with 10% heat-
inactivated fetal bovine serum, penicillin G (100 U/ml), streptomycin (100 g/
ml), L-glutamine, and nonessential amino acids at 37°C in 5% CO2.
The viruses used in this study included prototype DENV2 virus (New Guinea
C strain), prototype DENV3 (H87 strain), and prototype DENV4 (H241) (gifts
from Robert Shope, University of Texas at Galveston), one DENV1 high-pas-
sage clinical isolate (16007; gift from Robert Putnak, Walter Reed Army Insti-
tute of Research), one DENV1 clinical isolate from Sri Lanka (UNC 1002), three
DENV3 clinical isolates from Sri Lanka (UNC 3001, UNC 3009, and UNC
3011), and two DENV3 clinical isolates from Nicaragua (UNC 3017 and UNC
3018; gifts from E. Harris, University of California, Berkeley). All experiments
with the clinical virus isolates, unless otherwise stated, used stocks from viruses
that had been passaged in cell culture fewer than four times. Viral stocks were
obtained by inoculating a monolayer of C6/36 cells in a 75-cm2 tissue culture flask
with 200 l of virus diluted in 1 ml of EMEM–2% FBS. After 1 h, 14 ml of
EMEM supplemented with 2% FBS was added and the cells were cultured for 10
days at 28°C in 5% CO2. The supernatant was removed from the cells and
centrifuged for 5 min at 2,000  g to pellet cellular debris. The supernatant was
aliquoted and stored at 80°C. DENV1 (16007) was grown and passaged in
Vero cells, whereas DENV4 (H241) was grown in C6/36 cells as described above
and passaged one time in Vero cells.
The flavivirus group-reactive monoclonal antibody 4G2 (6) was purchased
from the American Type Culture Collection, Rockville, MD.
FACS titration assay. C6/36 cells were seeded in six-well plates and incubated
at 28°C in 5% CO2 until cells were approximately 90 to 95% confluent (1  106
cells/well). Medium was removed from cells, and 10-fold serial dilutions of virus
diluted in EMEM with 2% FBS to a final volume of 200 l were added to the
cells. The cells were incubated at 28°C in 5% CO2 for 1 h, and plates were rocked
every 15 min. The medium was removed, and the cells were washed in 1
phosphate-buffered saline (PBS). Two milliliters of EMEM with 2% FBS was
added to each well, and the cells were incubated for 24 h at 28°C in 5% CO2.
After 24 h the medium was removed and the cells were washed and scraped from
the well and resuspended in PBS. An aliquot of cells from each well was counted
using a hemocytometer. The remaining cells were centrifuged at 1,000  g for 5
min and resuspended in 200 l of Cytofix/Cytoperm solution (BD Biosciences,
San Jose, CA) and incubated on ice for 20 min in the dark. All subsequent steps
were performed in Cytoperm/Cytowash solution. The cells were centrifuged at
1,000  g for 5 min and washed two times before resuspending in 50 l of
fluorescein isothiocyanate (FITC)-labeled 4G2 monoclonal antibody for 1 h on
ice. The cells were washed two times and resuspended in the Cytoperm/Cytowash
solution. The samples were analyzed on a FACScan flow cytometer using Sum-
mit software. For each sample at least 100,000 events were collected. The linear
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range of the assay under the tested parameters was determined to be between
0.20% and 25% infected cells in a well (between 2,000 and 250,000 infected
cells per well), and sample wells outside this range were not used for determining
final titers. The titer of the virus was determined using the following formula:
FACS infectious units/ml  [(% of infected cells)  (total number of cells in
well)  (dilution factor)]/(volume of inoculum added to cells). Samples with a
titer below 1  104 infectious particles/ml cannot be analyzed with the FACS
assays, as this titer is below the level of detection.
Vero plaque assay. Vero plaque assays were performed using a modified
protocol from Wu et al. (18). Briefly, Vero cells were seeded in six-well plates at
a density of 2.5  105 cells/well and incubated overnight. Fifty microliters of
DENV stock was added to 450 l of diluent containing 1% bovine albumin in
DMEM–F-12 medium supplemented with penicillin and streptomycin. The virus
mixture was serially diluted using 10-fold dilutions. Two hundred microliters of
each dilution of virus was added to each well of Vero cells in duplicate. The
plates were incubated at 37°C in 5% CO2 for 1 h, rocking plates every 15 min.
Four milliliters of primary nutrient agar overlay (1% Seakem LE agarose, 20%
Earle’s balanced salt solution 10, 7% yeast extract-lactalbumin hydrolysate, 4%
FBS, 0.5% sodium bicarbonate, 1% gentamicin [50 mg/ml]) and 0.2% Fungizone
(12.5 g/ml) was added to each well, and the cells were incubated at 37°C in 5%
CO2 for 5 to 7 days. Next, 2 ml of a secondary nutrient agar overlay (primary
nutrient overlay containing 1% neutral red) was added to each well and the cells
were incubated overnight at 37°C in 5% CO2 before counting plaques and
calculating viral titers. The viral titers were expressed as PFU/ml, calculated as
[(number of plaques per well)  (dilution)]/(inoculum volume).
Endpoint titration assay. Endpoint titration assays were performed using a
modified protocol from Schoepp et al. (15). Briefly, C6/36 cells were seeded in a
96-well plate at a density of 1.3  105 cells/well in 225 l and incubated overnight
at 28°C in 5% CO2. Twenty-five microliters of virus was added to the first well,
and the virus was serially diluted using 10-fold dilutions. The plates were incu-
bated at 28°C in 5% CO2 for 5 days. To fix the plates, 50 l of a 3:1 acetone-PBS
mixture was added to each well, and the plates were incubated at 20°C for 20
min. The plates were air dried and washed with 1 PBS. The plates were blocked
with 5% FBS–PBS–0.05% NaN3 for 15 min at room temperature. Each well was
resuspended in 50 l of FITC-labeled 4G2 monoclonal antibody diluted in
blocking buffer and incubated for 1 h at 4°C. The plates were analyzed using an
inverted fluorescence microscope. Wells were scored for the presence or absence
of infection with either a positive or a negative symbol. Replicates of 10 were
performed for each virus. We calculated the 50% tissue culture infectious dose
(TCID50) of each virus using the Reed-Muench formula, based on immunoflu-
orescence: TCID50 (expressed as 10x/ml)  (dilution where % of infected wells
is 50%)  [(% of infected wells above 50%)  50%]/[(% of infected wells
above 50%)  (% of infected wells below 50%)]  log1010.
Plaque reduction neutralization test. The plaque reduction neutralization
tests were performed using modified protocols from Russell et al., Kochel et al.,
and Wu et al. (9, 14, 18). Vero cells were seeded in six-well plates at a density of
2.5  105 cells/well and incubated overnight. The test serum was heat inactivated
at 56°C for 30 min. The serum was serially diluted twofold in diluent containing
1% bovine albumin in DMEM–F-12 medium supplemented with penicillin and
streptomycin. DENV was diluted such that each well would be infected with 40
to 60 PFU. An equal volume of virus was added to the diluted serum and
incubated at 37°C in 5% CO2 for 1 h. The virus and antibody mixtures were
added to the Vero cells for 1.5 h. Four milliliters of primary nutrient agar overlay,
as described above, was added to each well and the cells were incubated at 37°C
in 5% CO2 for 6 days. Next, 2 ml of a secondary nutrient agar overlay (primary
nutrient agar overlay containing 1% neutral red) was added to each well and the
cells were incubated overnight at 37°C in 5% CO2 before counting plaques and
calculating viral titers. Each antibody concentration was tested in triplicate. The
numbers of plaques in each well were counted and the percent reduction was
determined as follows: % reduction  [(average number of control plaques 
average number of plaques for each dilution)/(average number of control
plaques)]  100. The plaque reduction neutralization titers of serum equaled the
reciprocal of the serum dilution in which either 50% (PRNT50) or 80%
(PRNT80) plaque reductions were observed.
FACS neutralization test (FNT). Vero cells were seeded in six-well plates at a
density of 2.5  105 cells/well and incubated overnight. Human serum to be
tested was heat inactivated at 56°C for 30 min. The serum was serial diluted
twofold in diluent containing 1% bovine albumin in DMEM–F-12 medium sup-
plemented with penicillin and streptomycin. DENV was resuspended in diluent
such that each well would receive a multiplicity of infection (MOI) of 0.1. An
equal volume of virus was added to the diluted serum and incubated at 37°C in
5% CO2 for 1 h. The virus and antibody mixture was added to the Vero cells.
Each antibody dilution was assayed in triplicate. The plates were incubated at
37°C in 5% CO2 for 1 h, rocking plates every 15 min. Two milliliters of DMEM–
F-12 containing 10% FBS was added to each well, and the plates were incubated
at 37°C in 5% CO2 for 24 h. Each well was washed with 1 ml of trypsin-EDTA.
Next, 0.2 ml of trypsin-EDTA was added to each well and incubated at 37°C for
5 min. One milliliter of chilled 1 PBS containing 10% FBS was added to each
well to inactivate the trypsin. The cells were pipetted to breakup any clumps and
centrifuged at 1,000  g for 5 min. The PBS was removed, and the cells were
fixed and stained for FACS as described above. Approximately 100,000 to
200,000 cells were analyzed for each sample. The percent reduction in the
number of infected cells was calculated for each serum dilution. The number of
infected cells in the wells infected with virus only was used to calculate the
percent reduction. The titers were expressed as the reciprocal of the serum
dilution that inhibited 50% (FNT50) or 80% (FNT80).
RESULTS
We conducted experiments to evaluate if FACS was a sen-
sitive method for detecting dengue virus infection of C6/36
mosquito cells. Cells were infected with prototype DENV2
(New Guinea C) and DENV3 (H87) lab-adapted strains at an
MOI of 0.05. Cells were harvested on days 1, 2, 3, 5, and 7 after
infection and analyzed by FACS. Representative FACS scatter
plots from DENV2- and DENV3-infected cells are depicted in
Fig. 1. Increasing numbers of infected cells were detected as
the infection progressed, indicating that the FACS assay was
suitable for following the kinetics of infection.
In the FACS assay DENV-infected cells were detected using
a monoclonal antibody (4G2) directed to the envelope (E)
glycoprotein of the virus. It is conceivable that some positive
cells detected by FACS may represent input virus binding to
cells and not productive infection of cells. Experiments were
performed with normal and UV-inactivated DENV2 to distin-
guish between infection and simple virus binding to cells. At
24 h postinfection (hpi) 5.20% of cells treated with normal
virus were positive, whereas no positive cells were detected
with UV-inactivated virus, indicating that simple binding of
input virus does not result in a positive signal in the FACS
assay (data not shown).
Titration of DENV by FACS. Ideally, a cell line for deter-
mining the titer of dengue virus by FACS should be highly
permissive for infection and infected by different strains of
virus with similar efficiencies. Otherwise, titers obtained for
different strains may reflect differences in interactions between
the viruses and cell line and may be a poor measure of the
absolute number of infectious particles. We chose the C6/36
mosquito cell line because the available evidence indicates no
dramatic differences in interactions between different strains
or serotypes of virus with this mosquito cell line. C6/36 cells
were infected with prototype DENV3 and clinical isolates of
DENV3 (MOI, 0.01), and the infection was monitored daily
for 7 days by FACS. The different strains of virus displayed
similar growth kinetics, indicating that this cell line was suit-
able for titrating DENV (Fig. 2). The DENV2 prototype strain
NGC displayed growth kinetics similar to the DENV3 isolates
in the C6/36 cell line (data not shown).
We reasoned that the number of cells infected early in in-
fection, before cell-to-cell spread of virus, would be a direct
measure of the number of infectious virus particles in an in-
oculum and that this number could be used to estimate viral
titer in a sample. Experiments were conducted to identify a
time point which was late enough for the input virus to have
infected cells and produced sufficient protein for detection by
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FACS, while being too early for release and cell-to-cell spread
of new virus. C6/36 insect cells were infected with DENV2
(strain NGC) at a high MOI, and the cells and supernatants
were collected at 9, 18, 24, 26, 30, and 46 hpi. The number of
infected cells increased from 9 to 24 hpi, and this first round of
infection plateaued between 24 and 30 hpi (Fig. 3). A second
round of infected cells was observed between 30 and 46 hpi.
New virus was first detected in medium at 24 hpi, and the
number of virus particles in the medium continued to increase
over time (Fig. 3). These results demonstrate that progeny
virions were first released into the medium at 24 h and that
these particles initiated a second round of cellular infection
that peaked at 46 hpi. We decided to harvest cells at 24 hpi for
the FACS titration assay, because the first round of infection
peaks at this time point and also because 24 hpi is too early to
detect cell-to-cell spread of virus. Previous studies have also
indicated that there is minimal cell-to-cell spread of DENV in
C6/36 cells at 24 hpi (8). Next, we determined if the FACS
assay was able to detect quantitative differences in the number
of virus particles in samples. Tenfold serial dilutions of proto-
type DENV2, DENV3, or clinical isolates of DENV3 were
added to C6/36 cells and the number of infected cells was
determined after 24 h. In initial experiments we used the pro-
totype DENV2 (NGC) and DENV3 (H87) strains. When cells
were infected with virus diluted 1:2, 1:20, and 1:200, decreasing
numbers of infected cells were detected by FACS (Fig. 4A).
Similar results were also obtained with clinical isolates of
DENV3 (Fig. 4B). Thus, a clear correlation was observed be-
tween the concentration of virus in the inoculum and the num-
ber of infected cells detected by FACS at 24 h after infection.
FIG. 1. Time course of DENV2 and DENV3 infection of C6/36
insect cells. C6/36 cells grown in six-well plates were infected with
DENV2 strain NGC and DENV3 strain H87 at an MOI of 0.05. One
well was mock infected to serve as a negative control. Cells were
harvested from duplicate wells on days 1, 2, 3, 5, and 7 and processed
for FACS. The cells were fixed and permeabilized using the Cytofix/
Cytoperm kit from BD Biosciences and stained for FACS using mono-
clonal antibody 4G2, which cross-reacts with all four DENV serotypes.
Cells were gated according to their size and granularity (x axis, side-
scattered cells; y axis, forward-scattered cells) to identify intact, single
cells. The gated cells were displayed on dot plots in which the x axis is
the forward scatter and y axis is fluorescence (FITC) intensity. The dot
plot was divided into four quadrants based on including 99.9% of the
uninfected control cells in the lower left quadrant. The percentage of
DENV-infected cells was determined by counting the number of cells
in the upper left quadrant and dividing this number by the total
number of cells in the dot plot.
FIG. 2. Infection of C6/36 cells by different strains of DENV. The
DENV3 prototype strain H87 as well as four primary DENV3 clinical
isolates were used to infect C6/36 cells at an MOI of 0.01. Cells were
harvested at 24-h intervals for 7 days, and infected cells were detected
by FACS.
FIG. 3. Time course of cell-to-cell spread of DENV2-infected
C6/36 insect cells. C6/36 cells grown in six-well plates were infected
with DENV2 strain NGC at an MOI of 2. Cells and supernatants were
harvested from wells at 9, 18, 24, 26, 30, and 46 h postinfection. The
cells were fixed and permeabilized using the Cytofix/Cytoperm kit from
BD Biosciences and stained for FACS using monoclonal antibody 4G2
to determine the percentage of infected cells; the results are expressed
as a continuous line with a closed circle. The amount of virus in the
supernatant at each time point was determined by plaque assay on
Vero cells and is expressed as a dashed line with a closed square.
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Comparison of the FACS assay to other standard dengue
virus titration assays. We estimated the FACS titer of each
virus stock using the following formula: titer (in infectious
units/ml)  [(% of infected cells)  (total number of cells in
well)  (dilution factor)]/(volume of inoculum added to cells).
Plaque formation on tissue culture monolayers (Vero, LLC-
MK2 [rhesus monkey kidney], and BHK [BHK 21, clone 15])
is the currently accepted method for titrating DENV. To fur-
ther validate the FACS assay, we compared the titers obtained
by FACS and plaque assay for different dilutions of the same
preparation of virus. For these experiments, initially we used
DENV2 NGC strain, which produces clear plaques on cell
monolayers. The virus stock was subjected to serial fivefold
dilutions, and an equal volume from each dilution was tested
by plaque and FACS assays. A linear relationship was observed
between the assays over 3 logs of titers ranging from 1  104 to
1  107 infectious particles or PFU/ml (Fig. 5), indicating that
the two assays were similar measures of infectious virus in a
sample. Furthermore, we observed that the effective range of
the FACS assay was when between 0.2 and 25% of cells were
infected (between 2,000 and 25,000 infected cells per well).
When the signal was below 0.2%, the assay was not sensitive
and displayed high variability (data not shown). When more
than 25% of the cells were infected, the assay was no longer
linear, presumably because the C6/36 cells became limiting in
the assay (data not shown). When titers for several strains of
DENV1, DENV2, DENV3, and DENV4 were determined by
FACS, plaque assay, and endpoint dilution assay, similar titers
were obtained with the different assays for DENV1 (strains
16007 and UNC 1002), DENV2 (NGC), DENV3 (strains UNC
3001, UNC 3009, and UNC 3011), and DENV4 (H241) (Table
1). For DENV3 strain H87, the titers obtained with the differ-
ent assays varied more than the titers of the other viruses
analyzed (Table 1).
FIG. 4. Titration of dengue virus using FACS. C6/36 cells were
infected with 10-fold serial dilutions of prototype strains and a clinical
isolate. At 24 hpi, cells were harvested, fixed, and stained for FACS
analysis. (A) Contour dot plots for DENV2- and DENV3-infected
cells were obtained from FACS analysis of infected C6/36 cells at 24 h
postinfection. C6/36 cells grown in six-well plates were infected for 24 h
using 10-fold serial dilutions of prototype strains NGC and H87. One
well served as a mock-infected control. The percentage of DENV-
infected cells was determined by counting the number of cells in the
upper left quadrant and dividing this number by the total number of
cells in the dot plot. At 24 h postinfection, the cells in the upper left
quadrant are likely a measure of the input virus, because this time
point is too early for cell-to-cell spread of newly assembled virus. The
dot plots shown above represent one experiment out of three and one
out of six experiments for DENV2 and DENV3, respectively.
(B) C6/36 cells grown in six-well plates were infected for 24 h using
10-fold serial dilutions of prototype strains NGC and H87 and clinical
isolates UNC 3001, UNC 3017, and UNC 3018.
FIG. 5. Comparison of FACS titration and plaque assay methods
for estimating DENV2 titers. A stock of DENV2 (1  107 PFU/ml)
was serially diluted fivefold, and each dilution was titrated on Vero
cells by plaque assay and on C6/36 cells by FACS. The lower limit of
detection by FACS is 10,000 infectious units per milliliter of inoculum.
The lower limit of detection by plaque assay is 50 PFU/ml.
TABLE 1. DENV titers determined by FACS, plaque assay, and
and point dilution
Strain
DENV titer based ona:
FACS Plaque assay Endpointdilution
DENV1 (16007) 1.5  107* 3.5  107* Not done
DENV1 (1002) 2.9  106* 1.7  106* Not done
DENV2 (NGC) 1.8  106 3.8  106 Not done
DENV3 (H87) 2.9  106 1.3  105 4.2  105
DENV3 (3001) 4.1  105 1.8  106 1.0  106
DENV3 (3009) 1.2  106 1.8  106 1.7  106
DENV3 (3011) 2.9  105 4.8  105* 1.1  106
DENV4 (H241) 9.7  106* 1.0  107* Not done
a Most values (exceptions are marked by an asterisk) are based on at least
three independent experiments.
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FACS-based assay to measure antibody neutralization of
DENV. Interactions between antibody and DENV play roles in
protective immunity and in antibody-dependent enhancement
of viral infection. A current method for measuring antibody
neutralization is the plaque reduction neutralization test on
Vero cells (PRNT). This assay is subject to the same limita-
tions as the plaque assay for virus titration. Experiments were
conducted to determine if the FACS titration assay could be
modified for measuring the ability of antisera to neutralize the
virus. The DENV2 NGC strain was incubated with serial two-
fold dilutions of human dengue virus immune or normal serum
before adding the virus to Vero cells. At each antibody dilution
the number of infectious virus particles was estimated by
FACS (24 hpi) and plaque assay (6 days postinfection). The
50% and 80% neutralization titers obtained with each method
were remarkably similar (Table 2).
DISCUSSION
Any assay for titrating a virus is a relative measure of infec-
tious virus that is defined by properties of the particular virus
and the methods used. The plaque assay, which has been the
standard method for titrating DENV, is time-consuming and
difficult to use with some primary clinical isolates. Here we
describe and validate a FACS-based assay for titrating DENV
that overcomes the limitations of the plaque assay. Viral titers
determined by FACS were similar to titers obtained by plaque
assay and endpoint dilution assay for some DENV strains but
not for others. We suspect that the ability of some strains to
infect the cell lines used for the different assays and/or differ-
ences in plaquing efficiency may account for the discordant
titers. Another explanation for the differences in viral titers
may be the time at which each experimental method was eval-
uated for viral infection. The FACS assay conducted at 24 h
after infection measures the ability of dengue virus particles to
enter a cell and produce viral antigen. The assay does not
require virus assembly or cell-to-cell spread. In contrast, to
obtain a positive signal in the endpoint dilution method, virus
particles have to enter cells and spread from cell to cell over a
period of 5 to 7 days. The FACS assay can only be used with
samples with a titer greater than 1  104 infectious units/ml. At
titers below 1  104/ml, the small number of infected cells in a
well were below the level of detection of the FACS assay. This
is a limitation of the FACS assay compared to the plaque assay,
which is more sensitive. Another limitation to the FACS assay
is that it requires costly equipment and trained staff and may be
difficult to establish in some settings. Even with its limitations,
FACS is still a powerful and effective tool for titrating virus.
The FACS assay provides the ability to measure infectious viral
titers as early as 24 h postinfection, whereas the plaque assay
requires 5 to 7 days. Additionally, the FACS assay can be used
to titrate clinical isolates that do not form clear plaques on cell
monolayers.
The current method for measuring the ability of antisera
to neutralize DENV is the PRNT assay. The PRNT assay is
subject to the same drawbacks as the plaque titration assay.
We report here that the FACS assay can also be adapted to
measure the ability of antisera to neutralize the virus. When
two human dengue virus immune sera were tested with the
FACS and plaque neutralization assays, similar neutraliza-
tion titers were obtained with both assays. Further studies
are needed to validate the FACS neutralization assay. Spe-
cifically, experiments need to be done with reference sera to
determine if the FACS neutralization assay can be used to
identify the infecting serotype of DENV and to distinguish
between primary and secondary infections. A major advan-
tage to a FACS neutralization assay is that it could be used
to measure neutralization of DENV isolates, irrespective of
their ability to form plaques. Compared to existing methods
for studying dengue virus, which work best with laboratory-
adapted strains, we hope the FACS-based methods de-
scribed here will greatly facilitate studies with primary clin-
ical isolates of dengue virus.
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